Clinical Trial Detail

NCT ID NCT02406508
Title Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Delcath Systems Inc.
Indications

hepatocellular carcinoma

Therapies

Melphalan

Sorafenib

Age Groups: adult

No variant requirements are available.